Role Summary
The Associate Director, Antibody Development will lead CMC strategy and execution for antibody and antibody-conjugate programs from sequence handoff through IND and early clinical supply. This role requires hands-on experience in cell line development, a solid understanding of upstream and downstream process development, and the ability to work closely with analytical, quality, regulatory, and external partners. This is a hybrid role based primarily in Cambridge, MA.
Responsibilities
- Lead CDMOs through CHO or other mammalian cell line development activities, including stable pool generation, clone selection, and MCB establishment.
- Provide clear guidance on clone selection strategy, expression systems, and overall development path.
- Work directly with external vendors supporting antibody and antibody-conjugate programs.
- Define clone selection criteria (productivity, product quality, stability) and partner with Discovery/Research to assess developability, manufacturability, expression, and comparability risks.
- Review development reports and batch documentation for upstream activities.
- Oversee cell line development & upstream process development to support tox and GMP campaigns at CRDMOs.
- Build scalability and comparability considerations into early development plans.
- Collaborate closely with analytical and process SMEs to guide method development for potency, purity, aggregates, glycosylation, and product variants.
- Align CMC timelines with overall program milestones and proactively identify technical risks and mitigation plans.
- Ensure documentation readiness for tech transfer and GMP manufacturing.
- Coordinate with Quality and Regulatory to support GMP and IND/CTA readiness.
Qualifications
- PhD in Molecular Biology, Biochemistry, Chemical Engineering, or related field (MS with significant experience considered).
- Minimum 8 years of relevant experience in antibody cell line and process development.
- Direct experience advancing biologics (preferably mAbs or related modalities) into IND/CTA.
- Deep experience with complex or challenging biologics modalities is strongly preferred.
- Strong working knowledge of CDMOs and CROs in the biologics space is required.
- Strong understanding of:
- CHO cell line development workflows
- Upstream and downstream process development
- Analytical characterization of biologics
- GMP manufacturing and regulatory expectations
- Demonstrated experience managing CDMOs.
- Working knowledge of ICH Q5, Q6, and Q8 principles.